TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment

MT Newswires Live

Jun 22

TScan Therapeutics (TCRX) said Monday that 11 of 14 patients undergoing allogeneic hematopoietic cell transplantation achieved complete donor chimerism within about 3 weeks of receiving an initial dose of TSC-101 in a phase 1 trial.

The treatment was well-tolerated with safety outcomes matching an earlier patient group and typical post-transplant side effects, TScan Therapeutics said.

The data "support our planned transition into the pivotal phase 3 study of TSC-101 this month," CEO Gavin MacBeath said.

TScan shares were 1.5% lower in premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2645949022"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645949022\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645949022?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645949022","market":"nz","top_or_hot":-1,"title":"TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment","media":"MT Newswires Live","content":"<html><body><p> TScan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TCRX) said Monday that 11 of 14 patients undergoing allogeneic hematopoietic cell transplantation achieved complete donor chimerism within about 3 weeks of receiving an initial dose of TSC-101 in a phase 1 trial.</p><p>The treatment was well-tolerated with safety outcomes matching an earlier patient group and typical post-transplant side effects, TScan Therapeutics said.</p><p>The data \"support our planned transition into the pivotal phase 3 study of TSC-101 this month,\" CEO Gavin MacBeath said.</p><p>TScan shares were 1.5% lower in premarket trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-22 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> TScan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TCRX) said Monday that 11 of 14 patients undergoing allogeneic hematopoietic cell transplantation achieved complete donor chimerism within about 3 weeks of receiving an initial dose of TSC-101 in a phase 1 trial.</p><p>The treatment was well-tolerated with safety outcomes matching an earlier patient group and typical post-transplant side effects, TScan Therapeutics said.</p><p>The data \"support our planned transition into the pivotal phase 3 study of TSC-101 this month,\" CEO Gavin MacBeath said.</p><p>TScan shares were 1.5% lower in premarket trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2645949022","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645949022","pubTimestamp":1782131484,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"TScan Therapeutics  said Monday that 11 of 14 patients undergoing allogeneic hematopoietic cell transplantation achieved complete donor chimerism within about 3 weeks of receiving an initial dose of TSC-101 in a phase 1 trial.The treatment was well-tolerated with safety outcomes matching an earlier patient group and typical post-transplant side effects, TScan Therapeutics said.The data \"support our planned transition into the pivotal phase 3 study of TSC-101 this month,\" CEO Gavin MacBeath said.TScan shares were 1.5% lower in premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","LENZ":"Therapeutics","TCRX":"Tscan Therapeutics, Inc.","BK4139":"生物科技","BK4007":"制药"},"translate_title":"TScan Therapeutics报告血癌治疗试验的积极数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TCRX":1,"LENZ":1.5},"content_text":"TScan Therapeutics (TCRX) said Monday that 11 of 14 patients undergoing allogeneic hematopoietic cell transplantation achieved complete donor chimerism within about 3 weeks of receiving an initial dose of TSC-101 in a phase 1 trial.The treatment was well-tolerated with safety outcomes matching an earlier patient group and typical post-transplant side effects, TScan Therapeutics said.The data \"support our planned transition into the pivotal phase 3 study of TSC-101 this month,\" CEO Gavin MacBeath said.TScan shares were 1.5% lower in premarket trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}